Skip to main content
. 2013 Dec 20;28(2):225–238. doi: 10.1210/me.2013-1319

Figure 3.

Figure 3.

GKirKO mice have an abnormal estrous cycle. A, Graphic representation of the estrous cycle in WT and GKirKO mice determined by vaginal cytology followed for 12 days (n = 5). B–E, Baseline serum LH and FSH levels in female (left, n = 6–8) and male (right, n = 3–10) mice. Assay detection limit = 0.048 ng/mL. F and H, GnRH stimulation test. Evaluation of serum LH levels 20 minutes after injection of GnRH agonist (0.1 ng/g via ip). Increased serum LH levels in mice treated with GnRH agonist (indicated as GnRH +) was observed in both genders of WT and GKirKO (n = 7–9). G and I, Kisspeptin stimulation test. Evaluation of serum LH levels 10 minutes after injection of kisspeptin-10 (1 nmol ip). No LH response to kisspeptin (indicated as Kiss +) was observed in female (n = 7–8) or male (n = 3–10) GKirKO mice. Significant differences compared with saline-treated control groups (indicated as GnRH − or Kiss −): *, P ≤ .05; **, P ≤ .01; ***, P ≤ .001. Two-way ANOVA showed an interaction between genotype and treatment in F (P ≤ .05), G (P ≤ .01), and I (P ≤ .001), an effect of treatment in F (P ≤ .01), G (P ≤ .05), H (P ≤ .001), and I (P ≤ .001) and an effect of genotype in G (P ≤ .001) and I (P ≤ .001).